These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 23136250)
1. Copy number and expression alterations of miRNAs in the ovarian cancer cell line OVCAR-3: impact on kallikrein 6 protein expression. Bayani J; Kuzmanov U; Saraon P; Fung WA; Soosaipillai A; Squire JA; Diamandis EP Clin Chem; 2013 Jan; 59(1):296-305. PubMed ID: 23136250 [TBL] [Abstract][Full Text] [Related]
2. Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas. Bayani J; Marrano P; Graham C; Zheng Y; Li L; Katsaros D; Lassus H; Butzow R; Squire JA; Diamandis EP Mol Oncol; 2011 Feb; 5(1):48-60. PubMed ID: 20800559 [TBL] [Abstract][Full Text] [Related]
3. Kallikreins as microRNA targets: an in silico and experimental-based analysis. Chow TF; Crow M; Earle T; El-Said H; Diamandis EP; Yousef GM Biol Chem; 2008 Jun; 389(6):731-8. PubMed ID: 18627289 [TBL] [Abstract][Full Text] [Related]
4. Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. White NM; Chow TF; Mejia-Guerrero S; Diamandis M; Rofael Y; Faragalla H; Mankaruous M; Gabril M; Girgis A; Yousef GM Br J Cancer; 2010 Apr; 102(8):1244-53. PubMed ID: 20354523 [TBL] [Abstract][Full Text] [Related]
5. Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes. Tamir A; Jag U; Sarojini S; Schindewolf C; Tanaka T; Gharbaran R; Patel H; Sood A; Hu W; Patwa R; Blake P; Chirina P; Oh Jeong J; Lim H; Goy A; Pecora A; Suh KS J Ovarian Res; 2014 Dec; 7():109. PubMed ID: 25477184 [TBL] [Abstract][Full Text] [Related]
6. KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes. Sidiropoulos KG; Ding Q; Pampalakis G; White NM; Boulos P; Sotiropoulou G; Yousef GM Mol Oncol; 2016 Aug; 10(7):993-1007. PubMed ID: 27093921 [TBL] [Abstract][Full Text] [Related]
7. Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects. Shan SJ; Scorilas A; Katsaros D; Diamandis EP Br J Cancer; 2007 Jan; 96(2):362-72. PubMed ID: 17242704 [TBL] [Abstract][Full Text] [Related]
8. Specific microRNA-mRNA Regulatory Network of Colon Cancer Invasion Mediated by Tissue Kallikrein-Related Peptidase 6. Sells E; Pandey R; Chen H; Skovan BA; Cui H; Ignatenko NA Neoplasia; 2017 May; 19(5):396-411. PubMed ID: 28431272 [TBL] [Abstract][Full Text] [Related]
9. Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer. Bayani J; Paliouras M; Planque C; Shan SJ; Graham C; Squire JA; Diamandis EP Mol Oncol; 2008 Oct; 2(3):250-60. PubMed ID: 19383346 [TBL] [Abstract][Full Text] [Related]
10. Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Seiz L; Dorn J; Kotzsch M; Walch A; Grebenchtchikov NI; Gkazepis A; Schmalfeldt B; Kiechle M; Bayani J; Diamandis EP; Langer R; Sweep FC; Schmitt M; Magdolen V Biol Chem; 2012 Apr; 393(5):391-401. PubMed ID: 22505521 [TBL] [Abstract][Full Text] [Related]
11. Kallikreins as markers of disseminated tumour cells in ovarian cancer-- a pilot study. Oikonomopoulou K; Scorilas A; Michael IP; Grass L; Soosaipillai A; Rosen B; Murphy J; Diamandis EP Tumour Biol; 2006; 27(2):104-14. PubMed ID: 16557045 [TBL] [Abstract][Full Text] [Related]
12. The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). Bayani J; Diamandis EP Clin Chem Lab Med; 2011 Nov; 50(2):211-33. PubMed ID: 22047144 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Nagahara H; Mimori K; Utsunomiya T; Barnard GF; Ohira M; Hirakawa K; Mori M Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6800-6. PubMed ID: 16203767 [TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer. Ahmed N; Dorn J; Napieralski R; Drecoll E; Kotzsch M; Goettig P; Zein E; Avril S; Kiechle M; Diamandis EP; Schmitt M; Magdolen V Biol Chem; 2016 Dec; 397(12):1265-1276. PubMed ID: 27483364 [TBL] [Abstract][Full Text] [Related]
15. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. White NM; Youssef YM; Fendler A; Stephan C; Jung K; Yousef GM Biol Chem; 2012 Apr; 393(5):379-89. PubMed ID: 22505520 [TBL] [Abstract][Full Text] [Related]
17. Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression. Agostini A; Brunetti M; Davidson B; Tropé CG; Heim S; Panagopoulos I; Micci F Oncotarget; 2017 Mar; 8(13):21554-21560. PubMed ID: 28423547 [TBL] [Abstract][Full Text] [Related]
18. Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients. Haritos C; Michaelidou K; Mavridis K; Missitzis I; Ardavanis A; Griniatsos J; Scorilas A Clin Exp Med; 2018 May; 18(2):203-213. PubMed ID: 29435805 [TBL] [Abstract][Full Text] [Related]
19. Study of kallikrein-related peptidase 6 (KLK6) and its complex with α1-antitrypsin in biological fluids. Korbakis D; Soosaipillai A; Diamandis EP Clin Chem Lab Med; 2017 Aug; 55(9):1385-1396. PubMed ID: 28672746 [TBL] [Abstract][Full Text] [Related]
20. Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer. Pandey R; Zhou M; Chen Y; Darmoul D; Kisiel CC; Nfonsam VN; Ignatenko NA Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]